Aprea Therapeutics, a Phase 3 biotech developing targeted therapies for cancer, announced terms for its IPO on Monday.
The Boston, MA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Aprea Therapeutics would command a fully diluted market value of $325 million.
Aprea Therapeutics was founded in 2002 and plans to list on the Nasdaq under the symbol APRE. J.P. Morgan, Morgan Stanley and RBC Capital Markets are the joint bookrunners on the deal. It is expected to price during the week of September 30, 2019.
